“Key issues on Biosimilars Guidelines development and current revision trends”
Provides an overview of the guidelines and norms set forth by the European Medicines Agency (EMA) for biotherapeutics & biosimilars
“Immunogenicity as a key issue for biotechnology-derived products”
Explains the concept of immunogenicity in biotherapeutics and gives an overview of relevant EU guidelines and norms
Good Manufacturing Practice (GMP) 2day course Jo Havemann
The following topics were presented to the participants through lectures, group discussions and exercises during 16 hours:
- Core values and guidelines of Good Laboratory Practice (GLP)
- Factors that might lead to questionable research & manufacturing practices and their impact
- GMP compliance, national & international regulations, guidelines and authorities
- Quality Management and Assessment
- Digital GMP Solutions
“Immunogenicity as a key issue for biotechnology-derived products”
Explains the concept of immunogenicity in biotherapeutics and gives an overview of relevant EU guidelines and norms
Good Manufacturing Practice (GMP) 2day course Jo Havemann
The following topics were presented to the participants through lectures, group discussions and exercises during 16 hours:
- Core values and guidelines of Good Laboratory Practice (GLP)
- Factors that might lead to questionable research & manufacturing practices and their impact
- GMP compliance, national & international regulations, guidelines and authorities
- Quality Management and Assessment
- Digital GMP Solutions
PIC/S is a combine term used for the execution of activities of Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme
harmonize, educate, and update aspects relating to Good Manufacturing Practice among member countries
harmonized relation among regulatory authorities and governments
members
history
role
objective and function
guidlines
Check out this presentation from PAREXEL Consulting experts to learn about key regulatory processes affecting biosimilars development including an an overview of the 351(k) Pathway, FDA approvals and managing post-approval challenges.
The European Commission Health and Consumers Directorate – General has published a draft “GUIDELINES ON THE PRINCIPLES OF GOOD DISTRIBUTION PRACTICES FOR ACTIVE SUBSTANCES FOR MEDICINAL PRODUCTS FOR HUMAN USE”.
The guideline addresses Quality systems, Personnel, Documentation, Order, Procedures, Records, Premises and Equipment, Receipts, Storage , Deliveries to Customers, Transfer of Information and Returns.
Following presentation is prepared by “ Drug Regulations” a non profit organization which provides free online resource to the Pharmaceutical Professional.
International Conference on Harmonisation (ICH) was created in 1990
Agreement between the EU, Japan, and the USA to harmonize different regional requirements for registration of pharmaceutical drug products.
This presentation highlights some of the changes in Therapeutic Goods (Standard for Tablets, Capsules and Pills) (TGO 101) Order 2019, compared to the previous Order, Therapeutic Goods Order No. 78 – Standard for tablets and capsules.
PIC/S is a combine term used for the execution of activities of Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme
harmonize, educate, and update aspects relating to Good Manufacturing Practice among member countries
harmonized relation among regulatory authorities and governments
members
history
role
objective and function
guidlines
Check out this presentation from PAREXEL Consulting experts to learn about key regulatory processes affecting biosimilars development including an an overview of the 351(k) Pathway, FDA approvals and managing post-approval challenges.
The European Commission Health and Consumers Directorate – General has published a draft “GUIDELINES ON THE PRINCIPLES OF GOOD DISTRIBUTION PRACTICES FOR ACTIVE SUBSTANCES FOR MEDICINAL PRODUCTS FOR HUMAN USE”.
The guideline addresses Quality systems, Personnel, Documentation, Order, Procedures, Records, Premises and Equipment, Receipts, Storage , Deliveries to Customers, Transfer of Information and Returns.
Following presentation is prepared by “ Drug Regulations” a non profit organization which provides free online resource to the Pharmaceutical Professional.
International Conference on Harmonisation (ICH) was created in 1990
Agreement between the EU, Japan, and the USA to harmonize different regional requirements for registration of pharmaceutical drug products.
This presentation highlights some of the changes in Therapeutic Goods (Standard for Tablets, Capsules and Pills) (TGO 101) Order 2019, compared to the previous Order, Therapeutic Goods Order No. 78 – Standard for tablets and capsules.
Increasing knowledge of genetics and cell processes leads to potential new biologic (and drug) targets at each step in the protein-production process. This leads to new therapies, which in turn lead to new understanding of diseases. Here is an update on relatively new drugs called biologics...
MARKETING AUTHORISATION, LICENSING AND QUALITY ASSESSMENT OF VACCINES IN INDI...Swapnil Fernandes
- European pharmaceutical legislation provides a comprehensive framework for the marketing authorisation of vaccines.
- In contrast to the European scenario, the Indian scenario for vaccines is relatively less regulated and follows the same process of approval as other biologics in spite of having a National Handbook for Vaccine Policy.
- Vaccine authorisation in the US, as is the case in EU, is a more straightforward process than in most other markets as the USFDA has provided vaccines with a distinct set of regulations in concerned areas of safety and quality.
“Evolution of biosimilar medicines assessment in Russia. Current practices and main challenges”
Illustrates the current Russian legislative scenario and ongoing developments on the regulation of biotherapeutics and biosimilars
Investigation of Medicinal Product Dossier (IMPD) and Investigator Brochure (...Tanvi Mhashakhetri
Contents:
European Medicines Agency (EMA)
IMPD Introduction
Contents of IMPD
Objectives
Scope
Introduction of IB
General Consideration
Content of IB
European Medicines Agency (EMA)
It is a decentralized agency of the European union.
The Management Board is the European Medicines Agency’s integral governance Body.
The Agency is responsible for the scientific evaluation, supervision and safety monitoring of the medicines developed by pharmaceutical companies use in EU.
EMA protects public and animal health in 27 EU member states, as well as the countries of the European economic area , by ensuring that all medicines available on the EU market are safe, effective and of high quality.
History
European medical agency was found in 1995, has worked across the EU and globally to protect public and animal healty by assessing medicines to rigorous scientific standards and providing with independent, science-based informations on medicines.
EMA has 20 year track record of ensuring efficacy and safety of human and veterinary medicines across Europe, and promoting research and innovation in the developments of medicines.
In first two decades, the agency recommended the authorization of the total of 975 humans and 188 veterinary medicines.
“WHO Standards for Regulatory Evaluation of Biotherapeutic Products including SBPs”
Provides an overview of the WHO activities & standards setting for biotherapeutic medicines & similar biotherapeutic product
ICH: Introduction, objectives & guidelines: A brief insight.RxVichuZ
This is my 44th powerpoint........deals with ICH guidelines.....
Deals with brief introduction, precise objectives, organization(in short) & guidelines (in precise), based on SAFETY, EFFICACY, QUALITY & MULTIDISCIPLINARY guidelines.
Happy reading!!
:)
Biosimilar a biological drug evaluation includes the biopharmaceutical families, the difference between small molecules and bio-pharmaceutical products, the regulatory requirements for biosimilars and the fact about biosimilars and biologic / bio pharmaceuticals the competent authorities and the key component of successful pharmacovigilane programs
IFPMA-TFDA Workshop on Couterfeit Medicines
‘Integrated Approach Against Fake Medicines’
Session 1: Current Regulatory Landscape & Initiatives Against Fake Medicines
On 6th February 2015
At Taipei International Convention Center
Taipei, Taiwan
IFPMA-TFDA Workshop on Couterfeit Medicines
‘Integrated Approach Against Fake Medicines’
Session4: Collaboration within and between countries
On 6th February 2015
At Taipei International Convention Center
Taipei, Taiwan
IFPMA-TFDA Workshop on Couterfeit Medicines
‘Integrated Approach Against Fake Medicines’
Session 4: Collaboration within and between countries
On 6th February 2015
At Taipei International Convention Center
Taipei, Taiwan
IFPMA-TFDA Workshop on Couterfeit Medicines
‘Integrated Approach Against Fake Medicines’
Session 4: Collaboration within and between countries
On 6th February 2015
At Taipei International Convention Center
Taipei, Taiwan
IFPMA-TFDA Workshop on Couterfeit Medicines
‘Integrated Approach Against Fake Medicines’
On 6th February 2015
At Taipei International Convention Center
Taipei, Taiwan
IFPMA-TFDA Workshop on Couterfeit Medicines
‘Integrated Approach Against Fake Medicines’
Session 3: Practices and Technologies for Prevention, Detection, Control and Monitoring of Fake Medicines.
On 6th February 2015
At Taipei International Convention Center
Taipei, Taiwan
IFPMA-TFDA Workshop on Couterfeit Medicines
‘Integrated Approach Against Fake Medicines’
On 6th February 2015
At Taipei International Convention Center
Taipei, Taiwan
IFPMA-TFDA Workshop on Couterfeit Medicines
‘Integrated Approach Against Fake Medicines’
Session 3: Practices and Technologies for Prevention, Detection, Control and Monitoring of Fake Medicines
On 6th February 2015
At Taipei International Convention Center
Taipei, Taiwan
IFPMA-TFDA Workshop on Couterfeit Medicines
‘Integrated Approach Against Fake Medicines’
On 6th February 2015
At Taipei International Convention Center
Taipei, Taiwan
IFPMA-TFDA Workshop on Couterfeit Medicines
‘Integrated Approach Against Fake Medicines’
Session 2: Supply Chain Integrity
On 6th February 2015
At Taipei International Convention Center
Taipei, Taiwan
IFPMA-TFDA Workshop on Couterfeit Medicines
‘Integrated Approach Against Fake Medicines’
Session 2: Supply Chain Integrity
On 6th February 2015
At Taipei International Convention Center
Taipei, Taiwan
IFPMA-TFDA Workshop on Couterfeit Medicines
‘Integrated Approach Against Fake Medicines’
On 6th February 2015
At Taipei International Convention Center
Taipei, Taiwan
IFPMA-TFDA Workshop on Couterfeit Medicines
‘Integrated Approach Against Fake Medicines’
Session 1: Current Regulatorz Landscape & Initiatives Against Fake Medicines
On 6th February 2015
At Taipei International Convention Center
Taipei, Taiwan
IFPMA Geneva Pharma Forum on 9 May 2014
Bringing Psoriasis into the Light
Presentation of Kim kjoeller, Senior Vice President
Global Development, Leo Pharma
IFPMA Geneva Pharma Forum on 9 May 2014
Bringing Psoriasis into the Light
Presentation of Professor Mahira Hamdy El Sayed
Dermatology and Venereology, Ain Shams University
David K. Robinson, Ph. D.Vice President, BiologicsHead and Executive Director, Biologics and Vaccines CMC RegulatoryMerck & Co, Inc.
Presenting on behalf of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)WCBP CASS, Washington DC, USAJanuary 2014
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
ABDOMINAL TRAUMA in pediatrics part one.drhasanrajab
Abdominal trauma in pediatrics refers to injuries or damage to the abdominal organs in children. It can occur due to various causes such as falls, motor vehicle accidents, sports-related injuries, and physical abuse. Children are more vulnerable to abdominal trauma due to their unique anatomical and physiological characteristics. Signs and symptoms include abdominal pain, tenderness, distension, vomiting, and signs of shock. Diagnosis involves physical examination, imaging studies, and laboratory tests. Management depends on the severity and may involve conservative treatment or surgical intervention. Prevention is crucial in reducing the incidence of abdominal trauma in children.
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Oleg Kshivets
Overall life span (LS) was 1671.7±1721.6 days and cumulative 5YS reached 62.4%, 10 years – 50.4%, 20 years – 44.6%. 94 LCP lived more than 5 years without cancer (LS=2958.6±1723.6 days), 22 – more than 10 years (LS=5571±1841.8 days). 67 LCP died because of LC (LS=471.9±344 days). AT significantly improved 5YS (68% vs. 53.7%) (P=0.028 by log-rank test). Cox modeling displayed that 5YS of LCP significantly depended on: N0-N12, T3-4, blood cell circuit, cell ratio factors (ratio between cancer cells-CC and blood cells subpopulations), LC cell dynamics, recalcification time, heparin tolerance, prothrombin index, protein, AT, procedure type (P=0.000-0.031). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and N0-12 (rank=1), thrombocytes/CC (rank=2), segmented neutrophils/CC (3), eosinophils/CC (4), erythrocytes/CC (5), healthy cells/CC (6), lymphocytes/CC (7), stick neutrophils/CC (8), leucocytes/CC (9), monocytes/CC (10). Correct prediction of 5YS was 100% by neural networks computing (error=0.000; area under ROC curve=1.0).
Adv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMSAkankshaAshtankar
MIP 201T & MPH 202T
ADVANCED BIOPHARMACEUTICS & PHARMACOKINETICS : UNIT 5
APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMS By - AKANKSHA ASHTANKAR
2. Dr. Carlo Pini - Superior Institute of Health (Italy)
1. Istituto Superiore di Sanità National Center forIstituto Superiore di Sanità National Center for Immunobiologicals Research and Evaluation-Immunobiologicals Research and Evaluation-CRIVIBCRIVIB 11Istituto Superiore di Sanità National Center forIstituto Superiore di Sanità National Center for Immunobiologicals Research and Evaluation-Immunobiologicals Research and Evaluation-CRIVIBCRIVIB 11
Key issues on Biosimilars
Guidelines development and
current revision trends
2. Istituto Superiore di Sanità National Center forIstituto Superiore di Sanità National Center for Immunobiologicals Research and Evaluation-Immunobiologicals Research and Evaluation-CRIVIBCRIVIB 22Istituto Superiore di Sanità National Center forIstituto Superiore di Sanità National Center for Immunobiologicals Research and Evaluation-Immunobiologicals Research and Evaluation-CRIVIBCRIVIB 22
Carlo Pini
(carlo.pini@iss.it)
Director
National Center for Immunobiologicals Research and
Evaluation - CRIVIB
Istituto Superiore di Sanità
Roma
Italian Delegate - Biologics Working Party (CHMP/BWP)
EMA - London
3. Istituto Superiore di Sanità National Center forIstituto Superiore di Sanità National Center for Immunobiologicals Research and Evaluation-Immunobiologicals Research and Evaluation-CRIVIBCRIVIB 33Istituto Superiore di Sanità National Center forIstituto Superiore di Sanità National Center for Immunobiologicals Research and Evaluation-Immunobiologicals Research and Evaluation-CRIVIBCRIVIB 33
Disclaimer
• The content of the following presentation represents
the speaker’s view and does not reflect any official
point of view.
• According to the EMA policy (0044 MA/513078/2010)
– No direct conflict of interest
– One indirect conflict of interest
4. Istituto Superiore di Sanità National Center forIstituto Superiore di Sanità National Center for Immunobiologicals Research and Evaluation-Immunobiologicals Research and Evaluation-CRIVIBCRIVIB 44Istituto Superiore di Sanità National Center forIstituto Superiore di Sanità National Center for Immunobiologicals Research and Evaluation-Immunobiologicals Research and Evaluation-CRIVIBCRIVIB 44
Biologicals/biotechnologicals and
biosimilarity
• Biologicals/biotechnologicals products are
complex molecules which cannot be fully
characterised from the analytical point of view
but whose quality attributes are also largely
defined by the manufacturing process.
• Therefore the “generics” concept, which is
well used for chemical entities, is not
applicable and the term “Biosimilar” has been
created
5. Istituto Superiore di Sanità National Center forIstituto Superiore di Sanità National Center for Immunobiologicals Research and Evaluation-Immunobiologicals Research and Evaluation-CRIVIBCRIVIB 55Istituto Superiore di Sanità National Center forIstituto Superiore di Sanità National Center for Immunobiologicals Research and Evaluation-Immunobiologicals Research and Evaluation-CRIVIBCRIVIB 55
Biosimilar products in Europe
• Article 10 (4) of Directive 2001/83 as amended by
2004/27.
Where a biological medicinal product which is similar to a
reference biological product does not meet the conditions
in the definition of generic medicinal products, owing to,
in particular, differences relating to raw materials or
differences in manufacturing processes of the biological
medicinal product and the reference biological medicinal
product, the results of appropriate pre-clinical tests or
clinical trials relating to these conditions must be
provided. The type and quantity of supplementary data to
be provided must comply with the relevant criteria stated
in the Annex and the related detailed guidelines. The
results of other tests and trials from the reference
medicinal product's dossier shall not be provided.
6. Istituto Superiore di Sanità National Center forIstituto Superiore di Sanità National Center for Immunobiologicals Research and Evaluation-Immunobiologicals Research and Evaluation-CRIVIBCRIVIB 66Istituto Superiore di Sanità National Center forIstituto Superiore di Sanità National Center for Immunobiologicals Research and Evaluation-Immunobiologicals Research and Evaluation-CRIVIBCRIVIB 66
Biosimilar products
• To support the biosimilarity approach, the biosimilar product
should be fully and extensively compared with the originator
at the quality level, but also at the non clinical and clinical level.
The size of the data to be provided is linked to the degree of
similarity which has been demonstrated at the quality level.
• This comparative approach (comparability exercise) should
take place during the first step of the development of the
biosimilar product, in order to avoid, in case of lack of
comparability at the quality level, unnecessary experiments in
animals (nonclinical) or not appropriate clinical trials
7. Istituto Superiore di Sanità National Center forIstituto Superiore di Sanità National Center for Immunobiologicals Research and Evaluation-Immunobiologicals Research and Evaluation-CRIVIBCRIVIB 77Istituto Superiore di Sanità National Center forIstituto Superiore di Sanità National Center for Immunobiologicals Research and Evaluation-Immunobiologicals Research and Evaluation-CRIVIBCRIVIB 77
Comparability exercise concept and application to
biosimilarity
• The comparability exercise concept was originally
developed to evaluate the impact of changes
introduced at the production process level within
a single manufacturer.
• It is based on a comparative analysis which is
carried out at the level of DS and/or DP using
“state of the art” suitable analytical approaches
• The same approach is followed but the
comparability exercise involves the biosimilar vs
the originator.
8. Istituto Superiore di Sanità National Center forIstituto Superiore di Sanità National Center for Immunobiologicals Research and Evaluation-Immunobiologicals Research and Evaluation-CRIVIBCRIVIB 88Istituto Superiore di Sanità National Center forIstituto Superiore di Sanità National Center for Immunobiologicals Research and Evaluation-Immunobiologicals Research and Evaluation-CRIVIBCRIVIB 88
European Medicines Agency (EMA) Approach
• Biosimilars are evaluated according to the centralised
procedure at EMA (2001/83)
• Documents (Guidelines and Concept Paper) have been
prepared
– General, defining the overall policy for biosimilars
– Module -specific, dealing with specific biosimilarity aspects on
quality, non clinical e clinical section
– Product-specific
• Erythropoietin, Growth hormones , G-CSF, insulin, interferon α, others.
– Issue (i.e. immunogenicity) - specific
• Quality is assessed at the CHMP/BWP level
• An ad hoc (BMWP) group was created for clinical aspects
• Final decision taken by the CHMP
9. Istituto Superiore di Sanità National Center forIstituto Superiore di Sanità National Center for Immunobiologicals Research and Evaluation-Immunobiologicals Research and Evaluation-CRIVIBCRIVIB 99Istituto Superiore di Sanità National Center forIstituto Superiore di Sanità National Center for Immunobiologicals Research and Evaluation-Immunobiologicals Research and Evaluation-CRIVIBCRIVIB 99
Main Guidelines
• Guideline on similar biological medicinal products
(CHMP/437/04)
• Guideline on similar biological medicinal products containing
biotechnology-derived proteins as active substance: quality
issues (CHMP/BWP/49348/2005)
• Guideline on similar biological medicinal products containing
Biotechnology-derived proteins as active substance: Non-
clinical and clinical issues (CHMP/BMWP/42832/2005)
• Guideline on immunogenicity assessment of Therapeutic
proteins (CHMP/BMWP/14327/06)
• Product-specific Non clinical and clinical Guidelines
10. Istituto Superiore di Sanità National Center forIstituto Superiore di Sanità National Center for Immunobiologicals Research and Evaluation-Immunobiologicals Research and Evaluation-CRIVIBCRIVIB 1010Istituto Superiore di Sanità National Center forIstituto Superiore di Sanità National Center for Immunobiologicals Research and Evaluation-Immunobiologicals Research and Evaluation-CRIVIBCRIVIB 1010
Guideline on similar biological
medicinal products (CHMP/437/04)
(30 October 2005)
Overarching Guideline
11. Istituto Superiore di Sanità National Center forIstituto Superiore di Sanità National Center for Immunobiologicals Research and Evaluation-Immunobiologicals Research and Evaluation-CRIVIBCRIVIB 1111Istituto Superiore di Sanità National Center forIstituto Superiore di Sanità National Center for Immunobiologicals Research and Evaluation-Immunobiologicals Research and Evaluation-CRIVIBCRIVIB 1111
CHMP/437/04
• The chosen reference medicinal product must be a medicinal
product authorised in the Community, on the basis of a
complete dossier in accordance with the provisions of Article
8 of Directive 2001/83/EC, as amended.
• The chosen reference medicinal product, defined on the basis
of its marketing authorisation in the Community, should be
used throughout the comparability program for quality, safety
and efficacy studies during the development of a similar
biological medicinal product in order to allow the generation
of coherent data and conclusions.
• Data generated from comparability studies with medicinal
products authorised outside the Community may only provide
supportive information.
12. Istituto Superiore di Sanità National Center forIstituto Superiore di Sanità National Center for Immunobiologicals Research and Evaluation-Immunobiologicals Research and Evaluation-CRIVIBCRIVIB 1212Istituto Superiore di Sanità National Center forIstituto Superiore di Sanità National Center for Immunobiologicals Research and Evaluation-Immunobiologicals Research and Evaluation-CRIVIBCRIVIB 1212
Selection of the originator
• The active ingredient of the biosimilar products must be as similar as
possible from the biological and molecular point of view to the
reference product.
• The pharmaceutical form, the concentration and the administration
route should be the same of the reference product .
• The analysis of the finished product, if available in suitable and useful
amount and quality (excipients, quantity, etc.) allows the
characterisation of the product itself, without gaining information on
the in process results and controls of the originator.
• It has to be remembered that a biological/biotechnological product is
defined not only by its quality attributes but also by the characteristics
of the process and by the results of the in process controls.
13. Istituto Superiore di Sanità National Center forIstituto Superiore di Sanità National Center for Immunobiologicals Research and Evaluation-Immunobiologicals Research and Evaluation-CRIVIBCRIVIB 1313Istituto Superiore di Sanità National Center forIstituto Superiore di Sanità National Center for Immunobiologicals Research and Evaluation-Immunobiologicals Research and Evaluation-CRIVIBCRIVIB 1313
Revision of Guidelines CHMP/437/04
(Overarching Guideline)
14. Istituto Superiore di Sanità National Center forIstituto Superiore di Sanità National Center for Immunobiologicals Research and Evaluation-Immunobiologicals Research and Evaluation-CRIVIBCRIVIB 1414Istituto Superiore di Sanità National Center forIstituto Superiore di Sanità National Center for Immunobiologicals Research and Evaluation-Immunobiologicals Research and Evaluation-CRIVIBCRIVIB 1414
CHMP/437/04 Rev. 1
15. Istituto Superiore di Sanità National Center forIstituto Superiore di Sanità National Center for Immunobiologicals Research and Evaluation-Immunobiologicals Research and Evaluation-CRIVIBCRIVIB 1515Istituto Superiore di Sanità National Center forIstituto Superiore di Sanità National Center for Immunobiologicals Research and Evaluation-Immunobiologicals Research and Evaluation-CRIVIBCRIVIB 1515
Main changes
• Clarification on the “biosimilar” approach
• Choice of the reference product
– Use of non -EEA authorised comparators as
supportive data.
– In this case a comparison between the EEA authorised
reference product, the non –EEA authorised comparator
and the proposed biosimilar should be carried out to
link the three different products
• Principles of establishing biosimilarity have been
expanded and detailed.
16. Istituto Superiore di Sanità National Center forIstituto Superiore di Sanità National Center for Immunobiologicals Research and Evaluation-Immunobiologicals Research and Evaluation-CRIVIBCRIVIB 1616Istituto Superiore di Sanità National Center forIstituto Superiore di Sanità National Center for Immunobiologicals Research and Evaluation-Immunobiologicals Research and Evaluation-CRIVIBCRIVIB 1616
Quality Guidelines
(CHMP/BWP/49348/2005)
• Biological/biotechnological products are macromolecules (up
to quaternary structure) and may undergo post-translational
modification (glycosylation).
• Biochemical and biophysical characterisation can be
performed on a comparative basis with great difficulty (i.e. the
non formulated active substance of the originator to allow
analysis not always available)
• Importance of the manufacturing process details (not
available for the originator)
• Immunogenicity of the biosimilar product as compared to the
originator
• Reference to Comparability Guideline (CPMP/ICH/5721/03)
17. Istituto Superiore di Sanità National Center forIstituto Superiore di Sanità National Center for Immunobiologicals Research and Evaluation-Immunobiologicals Research and Evaluation-CRIVIBCRIVIB 1717Istituto Superiore di Sanità National Center forIstituto Superiore di Sanità National Center for Immunobiologicals Research and Evaluation-Immunobiologicals Research and Evaluation-CRIVIBCRIVIB 1717
Comparability exercise: quality level
18. Istituto Superiore di Sanità National Center forIstituto Superiore di Sanità National Center for Immunobiologicals Research and Evaluation-Immunobiologicals Research and Evaluation-CRIVIBCRIVIB 1818Istituto Superiore di Sanità National Center forIstituto Superiore di Sanità National Center for Immunobiologicals Research and Evaluation-Immunobiologicals Research and Evaluation-CRIVIBCRIVIB 1818
Comparability exercise
• The demonstration of comparability does not necessarily mean
that the quality attributes of the pre-change and post-change
product are identical, but that they are highly similar.
• Comparison is performed that integrates and evaluates all data
collected, e.g., routine batch analyses, in-process control,
process validation/evaluation data, characterisation and
stability.
• The battery of tests for the comparability exercise should be
carefully selected and optimised to maximise the potential for
detecting relevant differences in the quality attributes of the
product
• It might be appropriate to apply more than one analytical
procedure to evaluate the same quality attribute and to add new
tests as a result of changes in quality attributes that the existing
methods are not capable of measuring.
19. Istituto Superiore di Sanità National Center forIstituto Superiore di Sanità National Center for Immunobiologicals Research and Evaluation-Immunobiologicals Research and Evaluation-CRIVIBCRIVIB 1919Istituto Superiore di Sanità National Center forIstituto Superiore di Sanità National Center for Immunobiologicals Research and Evaluation-Immunobiologicals Research and Evaluation-CRIVIBCRIVIB 1919
Biosimilar Products Guideline Rev.1 - quality
20. Istituto Superiore di Sanità National Center forIstituto Superiore di Sanità National Center for Immunobiologicals Research and Evaluation-Immunobiologicals Research and Evaluation-CRIVIBCRIVIB 2020Istituto Superiore di Sanità National Center forIstituto Superiore di Sanità National Center for Immunobiologicals Research and Evaluation-Immunobiologicals Research and Evaluation-CRIVIBCRIVIB 2020
Main changes
• Better clarification on the formulation issue
• Comparability section enlarged
• The concept of highly similar quality profile has
been introduced
• Some changes in the terminology
• Clarification that minor differences can be
acceptable
• Presence of quantitative and qualitative
differences discussed
• Target acceptance criteria justified
• Evolution of the reference product
21. Istituto Superiore di Sanità National Center forIstituto Superiore di Sanità National Center for Immunobiologicals Research and Evaluation-Immunobiologicals Research and Evaluation-CRIVIBCRIVIB 2121Istituto Superiore di Sanità National Center forIstituto Superiore di Sanità National Center for Immunobiologicals Research and Evaluation-Immunobiologicals Research and Evaluation-CRIVIBCRIVIB 2121
Non Clinical Guidelines
(CHMP/BMWP/42832/2005)
According to the outcome of the analytical evaluation of the
biosimilar:
• Case by case basis
• Non clinical studies can be reduced/omitted if the quality data
are strongly enough to support full biosimilarity
• They should be able to eventually identify specific aspects
which may represent a characteristic not present in the
originator
• in vitro e in vivo surrogate test in relation to specific aspects
• Animal models identical to those used by the originator.
22. Istituto Superiore di Sanità National Center forIstituto Superiore di Sanità National Center for Immunobiologicals Research and Evaluation-Immunobiologicals Research and Evaluation-CRIVIBCRIVIB 2222Istituto Superiore di Sanità National Center forIstituto Superiore di Sanità National Center for Immunobiologicals Research and Evaluation-Immunobiologicals Research and Evaluation-CRIVIBCRIVIB 2222
Clinical Guidelines
(CHMP/BMWP/42832/2005)
According to the outcome of the analytical evaluation
of the biosimilar
• Case by case basis
• End points and surrogate markers chosen on the
basis of the intended efficacy evaluation
• Immunogenicity
– Repeated administration
• The originator and the biosimilar must show the same
efficacy profile.
• A number of product specific guidelines are available
23. Istituto Superiore di Sanità National Center forIstituto Superiore di Sanità National Center for Immunobiologicals Research and Evaluation-Immunobiologicals Research and Evaluation-CRIVIBCRIVIB 2323Istituto Superiore di Sanità National Center forIstituto Superiore di Sanità National Center for Immunobiologicals Research and Evaluation-Immunobiologicals Research and Evaluation-CRIVIBCRIVIB 2323
Concept paper on the revision of
EMA/CHMP/BMWP/572828/2011
24. Istituto Superiore di Sanità National Center forIstituto Superiore di Sanità National Center for Immunobiologicals Research and Evaluation-Immunobiologicals Research and Evaluation-CRIVIBCRIVIB 2424Istituto Superiore di Sanità National Center forIstituto Superiore di Sanità National Center for Immunobiologicals Research and Evaluation-Immunobiologicals Research and Evaluation-CRIVIBCRIVIB 2424
Emerging issues
• The development of more complex biosimilar
medicinal products is challenging, and several issues in
the development are under re-evaluation
• selection of relevant species for non-clinical studies.
• need for clinical equivalence studies and other issues
of the design of the pivotal clinical studies, role of
biomarkers, amount of immunogenicity data needed,
and the possibility to extrapolate to other indications.
• WHO Guidelines
• 3R principle on animal use (replacement, reduction and
refinement)
25. Istituto Superiore di Sanità National Center forIstituto Superiore di Sanità National Center for Immunobiologicals Research and Evaluation-Immunobiologicals Research and Evaluation-CRIVIBCRIVIB 2525Istituto Superiore di Sanità National Center forIstituto Superiore di Sanità National Center for Immunobiologicals Research and Evaluation-Immunobiologicals Research and Evaluation-CRIVIBCRIVIB 2525
Critical issues for biosimilars
• A full and extensive chemical-physical analysis of the
product will hardly be sufficient to demonstrate per
se the similarity between the originator and the new
product
• Manufacturing process fundamental for a
biological/biotechnological product, not available for
the developer of the biosimilar
• in vivo Immunogenicity of the biosimilar is not
predictable as compared to the originator
• The size of the non clinical studies and of the clinical
trials required cannot be easily determined a priori
and could be quite large.
26. Istituto Superiore di Sanità National Center forIstituto Superiore di Sanità National Center for Immunobiologicals Research and Evaluation-Immunobiologicals Research and Evaluation-CRIVIBCRIVIB 2626Istituto Superiore di Sanità National Center forIstituto Superiore di Sanità National Center for Immunobiologicals Research and Evaluation-Immunobiologicals Research and Evaluation-CRIVIBCRIVIB 2626
Biosimilars
At least
• 14 authorised products (such as GH, EPO, G-
CSF, etc.)
• More products approaching including MoAbs
27. Istituto Superiore di Sanità National Center forIstituto Superiore di Sanità National Center for Immunobiologicals Research and Evaluation-Immunobiologicals Research and Evaluation-CRIVIBCRIVIB 2727Istituto Superiore di Sanità National Center forIstituto Superiore di Sanità National Center for Immunobiologicals Research and Evaluation-Immunobiologicals Research and Evaluation-CRIVIBCRIVIB 2727
Conclusions
• Biosimilar products are part of the European legislation and are well
separated from the generic medicinal product concept established for
“chemical entities”
• A number of general as well as specific guidelines are available. They
cover both the initial comparability assessment and the subsequent
development steps in terms of non clinical and clinical issues. Some of
them are under revision.
• The development of an increasing number of biosimilar products has
to be noticed. In particular MoAbs, close to the expiry date of the
patent have been already included in the pipeline
• The Marketing authorisation process at EMA does not foreseen any
less stringent assessment of the quality, safety and efficacy of a
biosimilar product as compared to an originator. Therefore the two
types of products undergo the same procedure under the same strict
scientific and regulatory conditions.